Blood markers shifted during glioblastoma treatment in a small study
Original title: Longitudinal plasma protein profiling in glioblastoma patients using NULISAseq reveals treatment-associated changes across radiation and chemotherapy.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
Blood was studied in a small group of patients, but no test is available yet.
The short version
A small study found that proteins in the blood changed as people went through radiation and chemotherapy.
What was studied. Researchers tested blood from 11 people with glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary after surgery. They also tested 15 healthy people, and measured 131 proteins at three points during treatment.
What they found. Before radiation, the glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary group had higher markers of brain cell injury and swelling. After radiation with the drug temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary, some immune signals rose, and a brain protein called BDNF dipped slightly. After more temozolomide, those immune signals calmed down and the injury markers fell.
What this means, and what it doesn't
What it could mean: Someday a simple blood test might help doctors see how treatment is affecting the brain. Right now, scans are the main way to check, and scans can be hard to read. This study points to blood markers that are worth studying further.
What it doesn't mean: This is not a new treatment, and it is not a cure. It was a very early study in only 11 patients. No blood test like this is available to patients today. The markers must be tested in much larger groups before any doctor could use them.
Source: PubMed, October 31, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.